Genetic therapies for neurodegenerative diseases: an interview with Sarah Tabrizi

Written by Sharon Salt, Editor

Since the groundbreaking results from IONIS-HTTRx (RG6042) for Huntington’s disease, genetic therapies for neurodegenerative diseases have become a remarkable avenue for potentially slowing and preventing disease. As more genetic therapies are surfacing in the field, we wanted to find out what the challenges are surrounding clinical trials for these therapies and what technological advancements could help bring them to the clinic sooner.   At the Wolfson Closing Symposium (19 June 2019, University College London, UK), we spoke with Sarah Tabrizi, who led the pioneering study of IONIS-HTTRx, to find out the answers to these questions. In addition to this, Sarah also provided her thoughts...

To view this content, please register now for access

It's completely free